Results 111 to 120 of about 19,200,433 (281)
On a p(x) $p(x)$-biharmonic problem with Navier boundary condition
Boundary Value Problems, 2018 In this paper, we study a p(x) $p(x)$-biharmonic equation with Navier boundary condition {Δp(x)2u+a(x)|u|p(x)−2u=λf(x,u)+μg(x,u)in Ω,u=Δu=0on ∂Ω. $$ \textstyle\begin{cases} \Delta^{2}_{p(x)}u+a(x)|u|^{p(x)-2}u= \lambda f(x,u)+\mu g(x,u)\quad \text{in ...
Zheng Zhou
doaj +1 more source
Existence and uniqueness of solution for p(x)-Laplacian problems
Boletim da Sociedade Paranaense de Matemática, 2014 This paper shows the existence of weak solution of a problem which involves the p(x)-laplacian with some dierent boundary conditions. The proof of the result is made by Browder Theorem.
Mostafa Allaoui +2 more
openaire +4 more sources
Molecular Oncology, EarlyView.Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source
The Dirichlet problem for the $p(x)$-Laplacian with unbounded exponent $p(x)$
We prove the solvability of the Dirichlet problem for the variable exponent $p$-Laplacian with boundary data in $W^{1,p(x)}(Ω)$ on a bounded, smooth domain $Ω\subset {\mathbb R}^n$. Our main focus will be on an a.e. finite variable exponent $p(\cdot)$ with $n < \inf\limits_{x\in Ω}p(x)$ and $\sup\limits_{x\in Ω}p(x) = \infty$ under the sole ...
Khamsi, M. +3 more
openaire +2 more sources
Sign changing solutions of the p(x)-Laplacian equation
Proceedings - Mathematical Sciences, 2013 zbMATH Open Web Interface contents unavailable due to conflicting licenses.
openaire +1 more source
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment
Molecular Oncology, EarlyView.This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley +1 more source
Advanced SciencePrecious metal‐based single‐atom catalysts (PM‐SACs) hosted in N‐doped carbon supports have shown new opportunities to revolutionize cathodic oxygen reduction reaction (ORR).
Chenming Fan +4 more
doaj +1 more source
Molecular Oncology, EarlyView.Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley +5 more
wiley +1 more source